Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,168,266
  • Shares Outstanding, K 103,177
  • Annual Sales, $ 1,176 M
  • Annual Income, $ -1,413 M
  • 60-Month Beta 0.85
  • Price/Sales 11.55
  • Price/Cash Flow N/A
  • Price/Book 2.30
Trade BGNE with:

Options Overview Details

View History
  • Implied Volatility 93.51% ( -2.81%)
  • Historical Volatility 85.35%
  • IV Percentile 94%
  • IV Rank 69.06%
  • IV High 119.52% on 03/14/22
  • IV Low 35.48% on 05/28/21
  • Put/Call Vol Ratio 3.42
  • Today's Volume 53
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 3,201
  • Open Int (30-Day) 2,740

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -4.38
  • Number of Estimates 3
  • High Estimate -4.30
  • Low Estimate -4.45
  • Prior Year -5.23
  • Growth Rate Est. (year over year) +16.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.00 +14.43%
on 05/12/22
178.79 -23.19%
on 04/29/22
-34.69 (-20.17%)
since 04/20/22
3-Month
120.00 +14.43%
on 05/12/22
221.81 -38.09%
on 02/23/22
-75.68 (-35.53%)
since 02/18/22
52-Week
120.00 +14.43%
on 05/12/22
426.56 -67.81%
on 09/17/21
-206.83 (-60.10%)
since 05/20/21

Most Recent Stories

More News
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new...

BGNE : 137.32 (+4.29%)
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients...

BGNE : 137.32 (+4.29%)
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

ALKS : 30.00 (+1.76%)
AMRN : 1.4200 (-1.39%)
BGNE : 137.32 (+4.29%)
DCPH : 11.84 (+4.13%)
BeiGene Reports First Quarter 2022 Financial Results

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the...

BGNE : 137.32 (+4.29%)
Why Earnings Season Could Be Great for BeiGene (BGNE)

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BGNE : 137.32 (+4.29%)
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week

Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.

HST : 18.61 (-4.32%)
VRTX : 258.59 (+1.23%)
CI : 259.49 (+1.02%)
EOG : 122.05 (+0.29%)
BGNE : 137.32 (+4.29%)
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients...

BGNE : 137.32 (+4.29%)
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide,...

BGNE : 137.32 (+4.29%)
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients...

BGNE : 137.32 (+4.29%)
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients...

BGNE : 137.32 (+4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 151.56
2nd Resistance Point 145.51
1st Resistance Point 141.41
Last Price 137.32
1st Support Level 131.26
2nd Support Level 125.21
3rd Support Level 121.11

See More

52-Week High 426.56
Fibonacci 61.8% 309.45
Fibonacci 50% 273.28
Fibonacci 38.2% 237.11
Last Price 137.32
52-Week Low 120.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar